FindTrial
Sign In

Using the High activity factor XI product for the bleeding therapy in inhibitor positive haemophilia patient

Using the High activity factor XI product for the bleeding therapy in inhibitor positive haemophilia patient

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036493
Enrollment
Unknown
Registered
2020-08-23
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding disease

Interventions

0:non

Sponsors

Ruijin Hospital Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: inhibitor positive haemophilia patient(congenital or acquired)

Exclusion criteria

Exclusion criteria: inhibitor negative haemophilia patient

Design outcomes

Primary

MeasureTime frame
Thrombin Generation test;—

Secondary

MeasureTime frame
liver function;—

Countries

China

Contacts

Public ContactXuefeng Wang

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

13641653074@139.com+86 13641653074

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026